KRAS and non-small cell lung carcinoma: In a phase II study involving 126 patients with KRAS p.G12C-positive advanced NSCLC who had prior platinum-based chemotherapy (with or without immunotherapy), subsequent treatment with sotorasib showed a partial response rate of 33.9% and complete response rate of 4.2% (88).